In a nutshell This study evaluated the safety and effectiveness of a new targeted therapy (INCB040093) with or without itacitinib in patients with relapsed or refractory (does not respond to treatment) lymphoma. This study concluded that this new agent was well-tolerated and showed promising effectiveness in these patients. Some background...
Read MoreCurrent treatment status-Undergoing active treatment-Progressive despite treatment Posts on Medivizor
Is daratumumab added to lenalidomide plus dexamethasone better in multiple myeloma?
In a nutshell This article investigated the safety and effectiveness of adding daratumumab (Darzalex) to lenalidomide (Revlimid) and dexamethasone (Decadron) for the treatment of relapsed or refractory (does not respond to treatment) multiple myeloma (RRMM). The authors concluded that the addition of daratumumab is safe and...
Read MoreEvaluating long-term outcomes of ibrutinib for relapsed or refractory mantle cell lymphoma
In a nutshell This study evaluated the long-term outcomes of ibrutinib (Imbruvica) treatment in patients with relapsed or refractory (does not respond to treatment) mantle cell lymphoma (MCL). This study concluded that ibrutinib is effective and well-tolerated in these patients. Some background MCL is a rare but aggressive type of non-Hodgkin’s...
Read MoreEvaluating resminostat for patients with relapsed or refractory Hodgkin’s lymphoma
In a nutshell This study evaluated the safety and effectiveness of resminostat in heavily pre-treated patients with relapsed or refractory (does not respond to treatment) Hodgkin’s lymphoma (HL). This study concluded that resminostat was effective and well-tolerated in these patients. Some background Histone deacetylase inhibitors (HDIs)...
Read MoreThe safety and effectiveness of bosutinib in patients with chronic myeloid leukemia
In a nutshell This study looked at the safety and effectiveness of bosutinib (Bosulif) in the treatment of chronic myeloid leukemia (CML). Researchers found that bosutinib was effective in patients who have failed other similar drug treatments. Some background Chronic myeloid leukemia (CML) is a cancer of the bone marrow. This can lead to abnormal...
Read MoreIs Daratumumab added to bortezomib plus dexamethasone better in treating multiple myeloma?
In a nutshell This article investigated the safety and effectiveness of adding daratumumab (Darzalex) to bortezomib (Velcade) and dexamethasone (Decadron) for the treatment of relapsed or refractory (does not respond to treatment) multiple myeloma (RRMM). The authors concluded that the addition of daratumumab is safe and gave the greatest benefit to...
Read MoreAdding inotuzumab ozogamicin with or without blinatumomab to chemotherapy for ALL.
In a nutshell This study looked at the effectiveness of adding inotuzumab ozogamicin (Besponsa) and blinatumomab (Blincyto) to low-intensity chemotherapy in the treatment of ALL. Researchers found that this combination of treatment was effective in these patients. Some background Acute lymphoblastic leukemia (ALL) is a cancer of the bone marrow. This...
Read MoreUse of specific T-cells in the treatment of ALL
In a nutshell This study looked at the use of specific T-cells to treat acute lymphoblastic leukemia. Researchers found that using these cells was effective in the treatment of these patients. Some background Acute lymphoblastic leukemia (ALL) is a type of cancer of the bone marrow. This can lead to abnormal cells in the immune system. It is often...
Read MoreIs blinatumomab safe and effective in the treatment of ALL?
In a nutshell This study looked at the safety and effectiveness of blinatumomab (Blincyto) in the treatment of unresponsive acute lymphoblastic leukemia (ALL). Researchers found that blinatumomab was safe and effective in the treatment of these patients. Some background Acute lymphoblastic leukemia is a type of cancer of the bone marrow. This can lead...
Read MoreIs regorafenib a safe option for the treatment of metastatic colorectal cancer?
In a nutshell This study investigated the effectiveness and safety of regorafenib (Stivarga) to treat patients with metastatic (spread to other parts of the body) colorectal cancer (mCRC) that progressed after initial treatment. Researchers suggested that regorafenib is a safe option to treat these patients. Some background The standard treatment...
Read MoreEvaluating survival outcomes after brentuximab vedotin treatment for relapsed or refractory Hodgkin’s lymphoma
In a nutshell This study evaluated the impact of brentuximab vedotin (Adcetris) on the survival of patients with relapsed or refractory (does not respond to treatment) classical Hodgkin’s lymphoma (cHL). This study concluded that brentuximab vedotin significantly improved survival in these patients. Some background Patients with cHL who...
Read MoreEvaluating the long-term outcomes of brentuximab vedotin after stem cell transplantation for classical Hodgkin’s lymphoma
In a nutshell This study evaluated the long-term survival and safety of brentuximab vedotin (Adcetris) treatment for patients with classical Hodgkin’s lymphoma (cHL) after autologous stem cell transplantation (auto-SCT; patient's own healthy stem cells are retrieved and then returned into the body after cancer has been removed with chemotherapy...
Read More
